A Phase 2 interventional study of SL-325 and Placebo in Crohn's Disease, sponsored by Shattuck Labs, Inc.. Recruiting at 20 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Shattuck Labs, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.
Among the 660 studies in Crohn Disease with a site in United States, this one is the 117th largest by planned enrollment of the 528 interventional ones that give a count, is one of 34 that started in 2026, is one of 141 in phase 2, reaches primary completion later than 104 of the 162 other live ones, and was the 655th registered.
1,995 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Agomab Spain S.L.U. · Sites in United States, Serbia, United Kingdom
Ages 18+
University of Miami · Sites in United States
Ages 16–75
The Cleveland Clinic · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, Australia, Brazil and 5 more countries
Ages 2–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
660 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 179 · Phase 3 134 · Phase 4 41
First in 1995; this study’s year is marked. 34 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 232 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 60 across the 528 interventional studies, 168 across the 128 observational. Of the 452 that completed or were terminated, 205 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
310 of 660 have an industry lead sponsor. The 10 most frequent:
Shattuck Labs, Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Shattuck Labs, Inc. has 1 study filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
59 of the studies in Crohn Disease with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT05660746Phase 3Children's Hospital Medical Center, CincinnatiPrecise Infliximab Exposure and Pharmacodynamic Control | 2027-03-31 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
Add all 59 to your calendar (.ics) → With an account.
Among the 660 studies in Crohn Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease.
The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SL-325
Drug: SL-325
Drug: SL-325
Drug: Placebo
SL-325 administered intravenously
Placebo administered intravenously
Proportion of participants who achieve endoscopic response
The proportion of participants who achieve endoscopic response, as defined by a ≥50% decrease in Simplified Endoscopic Score for Crohn's disease (SES-CD) from baseline.
Time frame: Week 12
Proportion of participants who achieve clinical remission
The proportion of participants who achieve clinical remission, as defined by a Crohn's Disease Activity Index \[CDAI\] score \< 150.
Time frame: Week 12
Incidence and severity of treatment-emergent adverse events
Incidence and severity of treatment-emergent adverse events (TEAEs)
Time frame: Week 12
Number of participants who discontinue study intervention due to an TEAE
Treatment-emergent adverse events (TEAEs) leading to discontinuation of study intervention
Time frame: Week 12
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement. Proposals will be reviewed based on scientific need, conflicts of interest, and regulatory approval status.
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Jul 2028, 20 months after the start.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 20 months is below that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 3-(2-(4-quinolin-3-yl)benzyl-1-oxoisoindolin-6-yl)-N-hydroxy-acrylamide
Shattuck Labs, Inc.